The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IWWM-12 2024 | Silencing GNAS to improve the efficacy of HDAC3 inhibitors in DLBCL and FL with wild-type CREBBP
Patrizia Mondello, MD, PhD, Mayo Clinic, Rochester, MN, discusses a study investigating the efficacy of HDAC3 inhibition in patients with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma, dependent on the presence of CREBBP mutations. The study found that silencing the GNAS gene could improve the efficacy of HDAC3 inhibitors, which are less effective in patients with wild-type CREBBP. This interview took place at the 12th International Workshop on Waldenström’s Macroglobulinemia (IWWM-12) in Prague, Czech Republic.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
